Literature DB >> 26216826

Long-term Morbidity of Testicular Cancer Treatment.

Chunkit Fung1, Sophie D Fossa2, Annalynn Williams3, Lois B Travis4.   

Abstract

Second malignant neoplasms, cardiovascular disease, neurotoxicity and ototoxicity, pulmonary complications, hypogonadism, and nephrotoxicity are potentially life-threatening long-term complications of testicular cancer and its therapy. This article describes the pathogenesis, risks, and management of these late effects experienced by long-term testicular cancer survivors, who are defined as individuals who are disease free 5 years or more after primary treatment. Testicular cancer survivors should follow applicable national guidelines for cancer screening and management of cardiovascular disease risk factors. In addition, health care providers should capitalize on the time of cancer diagnosis as a teachable moment to introduce and promote lifestyle changes.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease; Hypogonadism; Long-term morbidity; Nephrotoxicity; Neurotoxicity; Second malignant neoplasms; Survivorship; Testicular cancer

Mesh:

Substances:

Year:  2015        PMID: 26216826     DOI: 10.1016/j.ucl.2015.05.002

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  10 in total

1.  Testicular Cancer on the Web-an Appropriate Source of Patient Information in Concordance with the European Association of Urology Guidelines?

Authors:  Pia Paffenholz; Johannes Salem; Hendrik Borgmann; Tim Nestler; David Pfister; Christian Ruf; Igor Tsaur; Axel Haferkamp; Axel Heidenreich
Journal:  J Cancer Educ       Date:  2018-12       Impact factor: 2.037

2.  Long-Term Cognitive Functioning in Testicular Germ-Cell Tumor Survivors.

Authors:  Michal Chovanec; Lucia Vasilkova; Lucia Setteyova; Jana Obertova; Patrik Palacka; Katarina Rejlekova; Zuzana Sycova-Mila; Katarina Kalavska; Daniela Svetlovska; Silvia Cingelova; Beata Mladosievicova; Jozef Mardiak; Michal Mego
Journal:  Oncologist       Date:  2018-01-19

Review 3.  A systematic review of patient-reported outcome measures of neuropathy in children, adolescents and young adults.

Authors:  Donna L Johnston; Lillian Sung; Daniel Stark; A Lindsay Frazier; Abby R Rosenberg
Journal:  Support Care Cancer       Date:  2016-04-01       Impact factor: 3.603

Review 4.  Testicular cancer.

Authors:  Liang Cheng; Peter Albers; Daniel M Berney; Darren R Feldman; Gedske Daugaard; Timothy Gilligan; Leendert H J Looijenga
Journal:  Nat Rev Dis Primers       Date:  2018-10-05       Impact factor: 52.329

Review 5.  Long-term toxicity of cisplatin in germ-cell tumor survivors.

Authors:  M Chovanec; M Abu Zaid; N Hanna; N El-Kouri; L H Einhorn; C Albany
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976

6.  Locoregional surgical treatment improves the prognosis in patients with primary metastatic testicular cancer with a single bone or brain metastasis.

Authors:  Mierxiati Abudurexiti; Yao Zhu; Ding-Wei Ye
Journal:  Mol Clin Oncol       Date:  2020-06-03

7.  Prediction of Nephrotoxicity Associated With Cisplatin-Based Chemotherapy in Testicular Cancer Patients.

Authors:  Sara L Garcia; Jakob Lauritsen; Zeyu Zhang; Mikkel Bandak; Marlene D Dalgaard; Rikke L Nielsen; Gedske Daugaard; Ramneek Gupta
Journal:  JNCI Cancer Spectr       Date:  2020-04-23

8.  Protective role of N-acetylcysteine (NAC) on human sperm exposed to etoposide.

Authors:  João Baetas; Ana Rabaça; Ana Gonçalves; Alberto Barros; Mário Sousa; Rosália Sá
Journal:  Basic Clin Androl       Date:  2019-02-07

9.  The Connection Between Testicular Cancer, Minority Males, and Planned Parenthood.

Authors:  Wesley B Adams; Michael J Rovito; Mike Craycraft
Journal:  Am J Mens Health       Date:  2018-07-16

10.  Long-term Testis Cancer Survivors in Canada-Mortality Risks in a Large Population-based Cohort.

Authors:  Arnon Lavi; Roderick Clark; Tina Luu Ly; Shiva M Nair; Khalil Hetou; Michael Haan; Nicholas E Power
Journal:  Eur Urol Open Sci       Date:  2020-11-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.